<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37257710</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7573</ISSN><JournalIssue CitedMedium="Internet"><Volume>315</Volume><PubDate><Year>2023</Year><Month>Oct</Month><Day>28</Day></PubDate></JournalIssue><Title>Journal of ethnopharmacology</Title><ISOAbbreviation>J Ethnopharmacol</ISOAbbreviation></Journal><ArticleTitle>Efficacy of mecasin for treatment of amyotrophic lateral sclerosis: A phase IIa multicenter randomized double-blinded placebo-controlled trial.</ArticleTitle><Pagination><StartPage>116670</StartPage><MedlinePgn>116670</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jep.2023.116670</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0378-8741(23)00538-X</ELocationID><Abstract><AbstractText Label="ETHNOPHARMACOLOGICAL RELEVANCE" NlmCategory="BACKGROUND">Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disorder characterized by progressive paralysis of voluntary muscles. Mecasin, the extract of modified jakyakgamchobuja-tang-a herbal preparation comprising of Radix Paeoniae Alba, Radix Glycyrrhizae, Radix Aconiti Lateralis Preparata, Radix Salviae Miltiorrhizae, Rhizoma Gastrodiae, Radix Polygalae, Curcuma Root, Fructus Chaenomelis, and Rhizoma Atractylodis Japonicae-shows neuroprotective and anti-neuroinflammatory effects and alleviates the symptoms in patients with ALS.</AbstractText><AbstractText Label="AIM OF THE STUDY" NlmCategory="OBJECTIVE">This trial aimed to evaluate the efficacy and safety of mecasin in these patients.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Patients were randomized to receive mecasin 1.6&#xa0;g daily, mecasin 2.4&#xa0;g daily, or placebo for 12 weeks. The primary endpoint was the Korean version of ALS Functional Rating Scale-Revised (K-ALSFRS-R) score. The secondary endpoints were muscular atrophy measurements, pulmonary function test results, creatine kinase levels, body weight, safety, and scores of the Medical Research Council (MRC) scale for muscle strength; Visual Analog Scale for pain (VAS pain); Hamilton Rating Scale for Depression; and Fatigue Severity Scale.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 30 patients randomized, 24 completed the follow-up. Significant between-group differences were detected in the primary endpoint using the omnibus F-test. The changes in the K-ALSFRS-R score between 12 weeks and baseline were -0&#xb7;25, -1&#xb7;32, and -2&#xb7;78 in the mecasin 1.6&#xa0;g, mecasin 2.4&#xa0;g, and placebo groups, respectively. The difference in the K-ALSFRS-R score between the mecasin 1.6&#xa0;g and placebo groups was 2&#xb7;53 points (95% confidence interval [CI]: 0&#xb7;61-4&#xb7;45), and that between the 2.4&#xa0;g and placebo groups was 1&#xb7;46 points (95% CI: 0&#xb7;48-3&#xb7;40). However, no significant differences were detected in the secondary endpoints (MRC: dyspnea, p&#xa0;=&#xa0;0&#xb7;139; VAS pain, p&#xa0;=&#xa0;0&#xb7;916; forced vital capacity, p&#xa0;=&#xa0;0&#xb7;373). The incidence of adverse events was similar and low in all groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Mecasin may retard symptomatic progression without major adverse effects. A phase IIb study to evaluate its long-term effects in ALS is ongoing.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sungha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Research Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Muhack</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center of ALS/MND, Wonkwang University Gwangju Medical Hospital, Gwangju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ku</LastName><ForeName>Boncho</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Clinical Research Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cha</LastName><ForeName>Eunhye</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Center of ALS/MND, Wonkwang University Gwangju Medical Hospital, Gwangju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Wookcheol</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Center of ALS/MND, Wonkwang University Gwangju Medical Hospital, Gwangju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Son</LastName><ForeName>Ilhong</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, Wonkwang University Sanbon Hospital, Gyunggi-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Hyungwon</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Korean Neuropsychiatry Medicine, Wonkwang University, Jeollabuk-do, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Dongwoung</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Clinical Research Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Bongkeun</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Wonkwang University Gwangju Medical Hospital, Gwangju, 61729, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Chang-Sop</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Clinical Research Division, Korea Institute of Oriental Medicine, Daejeon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Sungchul</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Center of ALS/MND, Wonkwang University Gwangju Medical Hospital, Gwangju, Republic of Korea. Electronic address: kscndl@naver.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>J Ethnopharmacol</MedlineTA><NlmUniqueID>7903310</NlmUniqueID><ISSNLinking>0378-8741</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014797" MajorTopicYN="N">Vital Capacity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Mecasin</Keyword><Keyword MajorTopicYN="N">Neurodegenerative disorder</Keyword><Keyword MajorTopicYN="N">Paralysis</Keyword><Keyword MajorTopicYN="N">Placebo-controlled trial</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>1</Day><Hour>1</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>31</Day><Hour>19</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37257710</ArticleId><ArticleId IdType="doi">10.1016/j.jep.2023.116670</ArticleId><ArticleId IdType="pii">S0378-8741(23)00538-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>